Genelux Corporation (GNLX) Live Share Price, Invest From India

Genelux Corporation Stock Performance

as on July 13, 2026 at 2:16 pm IST

Day's Low
Day's High
$2.89
Day's Price Range
$3.04
$3.03
4.62%
Downside
0.33%
Upside
52 Week's Low
52 Week's High
$2.29
52-Week Price Range
$8.54
$3.03
24.42%
Downside
181.68%
Upside

Genelux Corporation share price movements today

Previous Close: $2.98
Open: $2.92
Volume: 1.1M
Day's Low - High: $2.89 - $3.04
52 Week Low - High: $2.29 - $8.54

Genelux Corporation Historical Returns

1 Month Return: + 2.36 %
3 Month Return: + 19.76 %
1 Year Return: -11.66 %
3 Year Return: -90.81 %
5 Year Return: 0 %

Genelux Corporation Stock Fundamentals & Key Indicators

Check Genelux Corporation market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$135.9M

EPS (TTM)

-0.815

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-34.4M

Revenue (TTM)

8.0K

Profit Margin

0.00%

Return On Equity TTM

-127.28%

Genelux Corporation vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Genelux Corporation with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Genelux Corporation	BUY	$135.9M	NA	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$39.9B	70.11%	75.25	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$123.2B	144.74%	28.82	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$69.7B	15.17%	16.24	29.65%	0.54%

Stock Returns calculator for Genelux Corporation Stock including INR - Dollar returns

The Genelux Corporation stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Genelux Corporation investment value today

Current value as on today

₹97,944

Returns

-₹2,056

(-2.06%)

Returns from Genelux Corporation Stock

-₹11,662 (-11.66%)

Dollar Impact

₹9,606 (+9.61%)

Analyst Recommendation on Genelux Corporation Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Genelux Corporation. Average target price of $17.5

Genelux Corporation Share Price Target

Get share price movements and forecasts by analysts on Genelux Corporation.

What analysts predicted

82.69%UPSIDE

Target Price

$17.5

Current Price

$3.03

Analyzed by

10 Analysts

Target

$17.50

Genelux Corporation target price $17.5, a slight upside of 82.69% compared to current price of $3.03. According to 10 analysts rating.

Indian Investors' Interest in Genelux Corporation Stock

Search interest for Genelux Corporation Stock has increased by 21% in the last 30 days, reflecting an upward trend in search activity.

Time period: June 13, 2026 to July 13, 2026

Change:21% versus previous 30 day period

Genelux Corporation Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	1	0	-	-	0	0	-	-	0	-
Gross Profit	0	0	0	0	0	0	0	-	0	0
Operating Income	-7	-8	-6	-6	-9	-7	-7	-8	-9	-8
EBITDA	-6	-7	-6	-6	-8	-7	-7	-7	-9	-7
Interest Expense	0	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-6	-7	-6	-6	-8	-7	-7	-7	-9	-7
Income Tax Expense	-4	0	-	-	-	-	-	-	-	-
Net Income	-6	-7	-6	-6	-8	-7	-7	-7	-9	-7
Net Profit Margin	-462.23%	-98125.00%	0.00%	0.00%	-1001.79%	-1657.52%	0.00%	0.00%	-115587.50%	0.00%

Genelux Corporation Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	11	0	0	0
Gross Profit	0	0	10	0	0	0
Operating Income	-12	-14	-3	-24	-31	-33
EBITDA	-11	-13	-1	-26	-28	-31
Interest Expense	1	1	1	3	-	-
Depreciation	0	0	0	1	0	0
Income Before Tax	-13	-16	-4	-28	-29	-32
Income Tax Expense	1	1	1	0	-	-
Net Income	-14	-17	-5	-28	-29	-32
Net Profit Margin	0.00%	0.00%	-47.05%	-16645.29%	-373362.50%	-401812.50%

Genelux Corporation Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-7	-6	-6	-8	-7	-7	-7	-9	-8
Operating Cash Flow	-4	-6	-5	-4	-5	-7	-6	-6	-6
Investing Cash Flow	-1	-17	3	6	3	-2	4	6	-8
Financing Cash Flow	0	27	-	0	9	0	-	0	18
Change in Cash	-5	3	-1	2	7	-9	-1	0	3

Genelux Corporation Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-13	-16	-5	-28	-29	-32
Operating Cash Flow	-7	-6	-3	-20	-21	-25
Investing Cash Flow	0	0	0	-14	-8	12
Financing Cash Flow	18	0	0	44	28	9
Change in Cash	10	-6	-4	9	0	-3

Global Institutional Holdings in Genelux Corporation

Funds	Holdings
Vanguard Group Inc	3.46%
Bleichroeder LP	3.08%
Vanguard Capital Management, LLC	3.78%
Northern Trust Corp	0.37%
Provident Wealth Management, LLC	0.35%

See all

Insights on Genelux Corporation

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -9.24M → -7.12M (in $), with an average increase of 29.8% per quarter
NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 19.3% return, outperforming this stock by 32.7%
NO EFFECT
Against Peers
In the last 3 years, Genelux Corporation Common Stock has experienced a drawdown of -91.0%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 86.0%
NEGATIVE IMPACT
Price Dip
In the last 3 years, GNLX stock has moved down by -91.0%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 896.0K → 8.0K (in $), with an average decrease of 73.9% per quarter

About Genelux Corporation

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Organisation	Genelux Corporation
Headquarters	2625 Townsgate Road, Westlake Village, CA, United States, 91361
Industry	Biotechnology
CEO	Mr. Thomas D. Zindrick J.D.
E-voting on shares	Click here to vote

Key Management of Genelux Corporation

Name	Title
Mr. Thomas D. Zindrick J.D.	Chairman, CEO & President
Mr. Matthew Pulisic M.B.A.	CFO and Principal Financial & Accounting Officer
Dr. Joseph Cappello Ph.D.	Chief Technical Officer
Dr. Yong Yu Ph.D.	Chief Scientific Officer
Mr. Eric Groen J.D.	General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development
Mr. Ralph Smalling B.Sc.	VP & Head of Regulatory Affairs
Dr. Jason B. Litten M.D.	Chief Medical Officer

FAQs

What is Genelux Corporation share price today?

Genelux Corporation share price today is $3.03 as on July 13, 2026 at 8:46 am IST at the close of the market. Genelux Corporation share today touched a day high of $3.04 and a low of $2.89.

What is the 52 week high and 52 week low for Genelux Corporation share?

Genelux Corporation share touched a 52 week high of $8.54 on November 5, 2025 and a 52 week low of $2.29 on March 30, 2026. Genelux Corporation stock price today i.e. July 13, 2026 at 8:46 am IST is closed at $3.03,which is 64.50% down from its 52 week high and 32.31% up from its 52 week low.

What is Genelux Corporation's market capitalisation today?

Genelux Corporation market capitalisation is $0.00T as on July 13, 2026 at 8:46 am IST.

How to invest in Genelux Corporation Stock (GNLX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Genelux Corporation on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Genelux Corporation Shares that will get you 0.4950 shares as per Genelux Corporation share price of $3.03 per share as on July 13, 2026 at 8:46 am IST.

What is the minimum amount required to buy Genelux Corporation Stock (GNLX) from India?

Indian investors can start investing in Genelux Corporation (GNLX) shares with as little as ₹95.37 or $1 (as of July 13, 2026 at 2:37 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹953.70 in Genelux Corporation stock (as per the Rupee-Dollar exchange rate as on July 13, 2026 at 2:37 pm IST). Based on Genelux Corporation share’s latest price of $3.03 as on July 13, 2026 at 8:46 am IST, you will get 3.3003 shares of Genelux Corporation. Learn more about fractional shares .